6.6K
Downloads
28
Episodes
From business publication BioProcess International comes The BioProcess Insider Expression Platform (BIEP). Editor Dan Stanton takes a look beyond the nuts and bolts of the biomanufacturing industry and speaks to some of the pioneers and thought leaders turning production on its head. www.bioprocessinsider.com
Episodes
Friday Feb 10, 2023
Friday Feb 10, 2023
With the celebration of International Day of Women and Girls in Science on 11th February 2023, we are excited to announce Informa’s latest podcast series produced on the BioProcess Insider Expression Platform (BIEP), where we dive into the complex journey of key female leaders shaping the life science industry.
Despite the progress over the last decade, gender parity remains a global issue throughout all levels within the science, technology, engineering, and mathematics (STEM) disciplines. Within academia, only 33.3% of all researchers are women, dwindling to a further 12% making national science academies. It is important to question how the industry is evolving, what progress has been made, and what steps we need to take next. This podcast will celebrate women and minorities in science and what more can be done to amplify their voices.
In this first episode of Voices of Biotech, we are joined by Deepa Talpade, VP, BD&L and Strategic Alliances of Oncology at Bayer who discusses the success of Bayer’s I&D Xcelerate program, launched by Marianne De backer two years ago, which promotes diversity through a 6–9-month placement within Bayer’s BD&L department.
Deepa also touches upon the socioeconomic impact deterring women to reach their full potential, the necessity to take a risk on women and the need for authenticity in leadership roles: “we should be allowed to colour ourselves in the way that we choose to”.
Thursday Jan 05, 2023
Ori Biotech: CGT accessibility, from platform to patient
Thursday Jan 05, 2023
Thursday Jan 05, 2023
This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Jason Foster, CEO of Ori Biotech. The company experienced a year of transition in 2022 with the closing of its $100 million Series B funding round and the expansion of its paperless cell and gene therapy (CGT) platform.
Foster speaks about the current process of taking the platform from clinical to commercial through feedback derived from its LightSpeed Early Access Program (LEAP) partners. He also discusses the issues surrounding accessibility, pricing, and supply chain fragility in the advanced therapies space.
The conversation moves on to talk about advanced therapies as both first and second-line treatments, in which Foster speaks about the hurdles created by the EU and US healthcare systems.
Thursday Nov 17, 2022
Ireland’s in the (up/down) stream: NIBRT talks bioproduction
Thursday Nov 17, 2022
Thursday Nov 17, 2022
The latest edition of the BioProcess Insider Expression Platform has NIBRT’s Killian O'Driscoll speaking on Ireland’s robust biomanufacturing environment, training programs, and vendor-led technologies.
Ireland has long established itself as a drug manufacturing hub and is home to commercial production sites run by Big Pharma firms including Pfizer, J&J, Eli Lilly, and AstraZeneca, as well as numerous third-party manufacturing organizations and bioprocess vendor firms.
The business environment has been spurred by low corporate tax rates, but also a highly skilled workforce, which has been supported by the government-funded National Institute for Bioprocessing Research and Training (NIBRT). The Dublin institution has been described as a ‘flight simulator for biomanufacturing,’ and has trained over 4,000 people a year in bioproduction processes since it opened in 2011.
At Biotech Week Boston in September, BioProcess Insider caught up with Killian O'Driscoll, director of Projects at NIBRT, who spoke to us in depth about Ireland’s pharma heritage, NIBRT’s international presence, and its relationship with vendors.
Monday Sep 12, 2022
Securing a CDMO with Pharmatech Associates (a CPhI WW preview)
Monday Sep 12, 2022
Monday Sep 12, 2022
Bikash Chatterjee and Stephanie Gaulding, CEO and MD at drug development consultancy firm Pharmatech Associates, talk about the different partnering and outsourcing strategies innovators can take, with a specific focus on smaller and mid-sized biotechs, which often don’t have the same level of in-built CMC expertise as Big Pharma. Whether you go with a single end-to-end CDMO or a multi-model approach, one thing is clear: know your product, know your needs and plan early.
This conversation originally took place as a Linkedin Live event ahead of the CPhI Worldwide conference happening in Frankfurt in November.
Friday Aug 12, 2022
Friday Aug 12, 2022
This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Stuart Curbishley, head of business and project development, advanced therapies at University of Birmingham and Ivan Wall, CEO, Four-Plus and director of the National Training Center for advanced therapies manufacturing.
We delve deep into the challenges concerning training talent in the advanced therapy and wider biopharma space, potential solutions that could filter the staffing bottleneck, and how the respective institutions are responding to these issues.
Wednesday Jul 20, 2022
Snippets from BIO: Lumen CEO talks edible antibodies
Wednesday Jul 20, 2022
Wednesday Jul 20, 2022
Another interview taken from the BioProcess International Theater at BIO, in June 2022.
This time, I sat down with Brian Finrow, the Co-Founder and CEO of Lumen Biosciences - a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology.
The firm is developing ‘oral antibodies’ using its platform based on spirulina – the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories that churn out therapeutic antibodies.
Friday Jul 15, 2022
Snippets from BIO: Cytiva’s Emmanuel Ligner on Biopharma resilience
Friday Jul 15, 2022
Friday Jul 15, 2022
Emmanuel Ligner, CEO of self-described bioprocess critical actor Cytiva, talks us through the changing biomanufacturing landscape and unveils his firm’s sustainability report during a fireside chat at the BioProcess International Theater at BIO in June
Friday Jul 08, 2022
Snippets from BIO 22: Fujifilm Diosynth’s Martin Meeson
Friday Jul 08, 2022
Friday Jul 08, 2022
In the first of my series of interviews from BIO 2022 in San Diego, I speak with Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, one of the most prominent contract development and manufacturing organizations (CDMOs).
He talks about the CDMO's part in battling COVID-19, the major capital expenditure projects underway at facilities in Denmark, North Carolina, and elsewhere, and Fujifilm's presence in the advanced therapies space, and why it has chosen to invest in mRNA, gene therapies, and allogeneic -- but not autologous -- cell therapy capabilities.
Wednesday May 25, 2022
Opening the gates for women in biotech, with Nadine Ritter
Wednesday May 25, 2022
Wednesday May 25, 2022
There is no lack of talented women in the biotech space but the gates blocking their progression must be open for them to fully realize their potential.
“Career development is an integral part of DEI because it’s diversity inclusion at the starting gate,” rather than just a tick-box exercise among the C-suite, said Nadine Ritter, president and analytical advisor at Global Biotech Experts at a DEI coffee morning at BPI Europe in Vienna. “It will never really change at the top unless we remediate the gates [below].”
This podcast is the full conversation with BioProcess Insider reporter Millie Nelson
Wednesday May 04, 2022
The changing dynamics between drug sponsors and their CDMO partners
Wednesday May 04, 2022
Wednesday May 04, 2022
Over the past decade, the relationships drug developers have with their third-party biomanufacturers has evolved from relatively simple transactional services to integrated and complex strategic partnerships.
This podcast replays a panel discussion from EBD's BIO EUROPE Spring event where editor Dan Stanton discusses the changing way pharma works with CDMOs with delegates from Samsung Biologics, Catalent, and AGC Biologics.
Topics covered include: The history of CDMOs, M&A within the industry, the advent of new modalities and, of course, the COVID-19 pandemic.